MD Desk

    Indian Medicines Pharmaceutical Corporation Ltd. (IMPCL), a CPSE under the administrative Control of Ministry of Ayush, Govt. of India is engaged in Manufacturing and Marketing of Ayurvedic and Unani Medicines. IMPCL is profit making organization since its inception.

IMPCL has surpassed all records, in-terms of Production, Turnover and Profit establishing that the Organisation is committed to excel in the years to come.

   The Financial Year 2021-22, which has been a record year in terms of turnover and profit but has been a difficult year in terms of operations due to the continued impact of COVID. However the Company with all the limitations has performed well beyond expectation.

   The Profit before tax of IMPCL was Rs. 45 Lakh during the year 2019-2020, which surged to Rs. 45.41 Crore for the year 2021-2022, at a 100 fold increase.The efforts put together has contributed to the highest ever turnover of Rs. 260.84 for the year 2021-22. An increase of over 59% over the previous year’s turnover of Rs.164.02 Crore. The current profit of Rs. 45.41 Crore is almost thrice the year’s 2020-2021 profit of Rs. 15.69 Crore.

    The company has recommended the highest ever Dividend payment of 30% of Profit after Tax of Rs. 33.76 Crore for the year 2021-22 and paid Rs10.13Crore to its Share Holders. The dividend has been apportioned to Rs. 9.94 Crore to Government of India (Bharat Kosh) and Rs19.09 Lakhs to Government of Uttarakhand (M/s KMVN Ltd).

    IMPCL is the only CSPE whose price/rate has been successfully accepted in the GeM portal for procurement purposes and products are available for procurement of medicines. IMPCL contributed to PM-BJP during pandemic and made the Bal Raksha Kit, AyurRaksha Kit, Ayush 64 available to all Jan Ausadhi Kendra across the country. IMPCL ensured availability of AyurRaksha Kit for Polling Parties based on requirement across all the Polling Booths of Uttar Pradesh. During Elections which concluded in March 2022. Ayur Care kit was made available against Ministry of Ayush requirement within the shortest period of time that is 10 days during the third wave of Pendamic.

    With our strong commitment and unmatched product portfolio, we have been effectively managing our business, regardless of the operating environment and relentlessly working towards higher Goals set for ourselves for the years to come.

    Like previous years, the Company has a strong commitment towards environment sustainability and social development.

    Speaking on the occasion, of Dividend Distribution on the 10th. Of November, Union Minister of Ports, Shipping & Waterways and Ayush, Sri.Sarbananda Sonowal said, “The performance by IMPCL is a true realisation of the vision that our dynamic Prime Minister Shri Narendra Modi ji envisaged for the traditional Indian medicine sector. As we strive towards enabling our rich heritage of traditional medicine towards enrichment of human lives, it is important that IMPCL plays its important part to keep the supply chain of traditional medicine in flow with quality medicines. I commend the entire team of the company for this wonderful feat this year and I hope this is the only beginning of a great turnaround story that IMPCL can unravel in the days to come. We must all work hard to enabling our healthcare system in order to achieve the objective of Swastha Bharat as per the vision of Prime Minister Shri Narendra Modi ji.”


            With Kind Regards,

(Dr. Mukesh Kumar)

Managing Director



Last Updated on : 11/11/2022